Tissue Therapies Limited was formed in 2003 to commercialise Tissue Culture and Repair technology from the Queensland University of Technology (QUT) in Brisbane, Australia. Tissue Therapies provides tissue culture and repair technology through a novel growth factor platform technology, VitroGro?.

Tissue Therapies has the exclusive worldwide licence to patents for 'Growth Factor Complex' and 'Modulation of Cell Migration and Growth.' These core cell-based bio-technologies will be used to develop high-value products and services for laboratory, industrial and medical applications by building upon the expertise of the core start-up team, by outsourcing resources and skills and through international collaborations.

Tissue Therapies new direction is towards a number of skin and wound applications, including skin and corneal grafts as well as diabetic and venous ulcers. The proliferation of progenitor cells in vitro and in vivo on biodegradable microspheres, prosthetics and implants coated with VitroGro? will also be explored. VitroGro?, the core technology of Tissue Therapies, is a novel growth factor platform technology applicable in medical and research markets in the areas of:

• wound healing
• tissue regeneration
• cosmetic and reconstructive surgery
• autologous cell therapies
• research cell culture applications (eg. stem cells) requiring growth reagents

This exclusive technology will deliver growth-enhancing factors to cells, tissues and patients via a patented complex based on the protein vitronectin.